https://scholars.lib.ntu.edu.tw/handle/123456789/496059
標題: | Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: A retrospective cohort analysis | 作者: | CHIN-HSIAO TSENG | 關鍵字: | Colorectal cancer; Diabetes mellitus; Metformin; Taiwan | 公開日期: | 2017 | 出版社: | Elsevier Masson SAS | 卷: | 43 | 期: | 5 | 起(迄)頁: | 438-445 | 來源出版物: | Diabetes and Metabolism | 摘要: | Background The association between metformin and colorectal cancer (CRC) has rarely been investigated in Asian populations. Methods This retrospective cohort study included patients with newly diagnosed type 2 diabetes during 1999–2005, recruited from Taiwan's National Health Insurance database. A total of 169,601 patients (original cohort: 153,270 ever-users and 16,331 never-users of metformin) and a subgroup of 1:1 propensity-score-matched pairs of 16,331 ever-users and 16,331 never-users (matched cohort) were followed up to 31 December 2011. Cox regression was constructed with the inverse probability of treatment-weighting, using propensity scores, and was used to estimate hazard ratios (HRs). Results In the original cohort, the incidence of CRC was 242.9 and 480.9 per 100,000 person-years, respectively, in ever- and never-users. The overall HR [0.50, 95% confidence interval (CI): 0.45–0.56] suggested a significantly lower risk in metformin users, while compared with never-users, the HR (95% CI) for the first (<27.1 months), second (27.1–58.1 months) and third (>58.1 months) tertiles of cumulative duration of metformin therapy was 0.86 (0.76–0.98), 0.51 (0.45–0.59) and 0.26 (0.23–0.30), respectively. Analyses in the matched cohort showed similar findings with an overall HR of 0.62 (0.53–0.74), and a tertile analysis HR of 1.02 (0.81–1.28), 0.70 (0.56–0.89) and 0.32 (0.23–0.43), respectively. Re-analyses using more stringent diagnoses of CRC and cumulative duration as a continuous variable have consistently supported a protective effect with metformin use. Conclusion Metformin is associated with a lower frequency of CRC. ? 2017 Elsevier Masson SAS |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018637845&doi=10.1016%2fj.diabet.2017.03.004&partnerID=40&md5=eb0f755adf3ee61ae88e5b5b41a25d35 https://scholars.lib.ntu.edu.tw/handle/123456789/496059 |
ISSN: | 1262-3636 | DOI: | 10.1016/j.diabet.2017.03.004 | SDG/關鍵字: | metformin; antidiabetic agent; metformin; adult; Article; cancer grading; cancer incidence; cancer risk; cancer staging; cohort analysis; colorectal cancer; controlled study; dose response; drug use; female; follow up; hazard ratio; human; ICD-9-CM; major clinical study; male; non insulin dependent diabetes mellitus; retrospective study; risk assessment; risk reduction; Taiwan; terminal disease; aged; colorectal tumor; factual database; incidence; middle aged; non insulin dependent diabetes mellitus; propensity score; risk; Taiwan; Aged; Colorectal Neoplasms; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Propensity Score; Retrospective Studies; Risk; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。